#######################
# Document Properties #
#######################
SET DOCUMENT Copyright = "Copyright © 2018 Fraunhofer Institute SCAI, All rights reserved."
SET DOCUMENT Licenses = "Private Ownership to Fraunhofer Institute SCAI"
SET DOCUMENT ContactInfo = "charles.hoyt@scai.fraunhofer.de"

SET DOCUMENT Name = "Nicotinic Receptor Abnormalities of Alzheimer’s Disease: Therapeutic Implications"
SET DOCUMENT Version = "1.0.0"
SET DOCUMENT Description = ""
SET DOCUMENT Authors = "Sandra Spalek"

##############
# Namespaces #
##############

# Namespaces hosted on https://github.com/pharmacome/terminology
# --------------------------------------------------------------
DEFINE NAMESPACE CHEBI          AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/chebi-names.belns"
DEFINE NAMESPACE DRUGBANK       AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/drugbank-names.belns"
DEFINE NAMESPACE ECCODE         AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/ec-code.belns"
# DEFINE NAMESPACE FB           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/80171ae62cf43aa1fc8a6c326b94537ab342458c/external/fb-names.belns"
DEFINE NAMESPACE HBP            AS URL "https://raw.githubusercontent.com/pharmacome/terminology/7e4be528f12abd28be768b62402fba6e083eaf9e/export/hbp-names.belns"
DEFINE NAMESPACE HGNC           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/hgnc-names.belns"
DEFINE NAMESPACE HGNCGENEFAMILY AS URL "https://raw.githubusercontent.com/pharmacome/terminology/3074b85b858455d8eeb76cfcdef685ced19bbe11/external/hgnc.genefamily-names.belns"
DEFINE NAMESPACE GO             AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/go-names.belns"
DEFINE NAMESPACE INTERPRO       AS URL "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/interpro-names.belns"
DEFINE NAMESPACE MESH           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/8ccfed235e418e4c8aa576f9a5ef0f838e794c7f/external/mesh-names.belns"
DEFINE NAMESPACE MGI            AS URL "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/mgi-names.belns"
DEFINE NAMESPACE MIRBASE        AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/mirbase-names.belns"
DEFINE NAMESPACE NCBIGENE       AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/entrez.belns"
DEFINE NAMESPACE PFAM           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/8ccfed235e418e4c8aa576f9a5ef0f838e794c7f/external/pfam-names.belns"
DEFINE NAMESPACE RGD            AS URL "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/rgd-names.belns"

# Namespaces hosted on https://github.com/sorgerlab/famplex
# ---------------------------------------------------------
DEFINE NAMESPACE FPLX           AS URL "https://raw.githubusercontent.com/sorgerlab/famplex/e8ae9926ff95266032cb74f77973c84939bffbeb/export/famplex.belns"

# Namespaces hosted on https://arty.scai.fraunhofer.de/artifactory/bel/namespace
# ------------------------------------------------------------------------------
DEFINE NAMESPACE CTO            AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/clinical-trial-ontology/clinical-trial-ontology-1.0.0.belns"
DEFINE NAMESPACE DO             AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/disease-ontology/disease-ontology-20170725.belns"
DEFINE NAMESPACE HP             AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/hp/hp-20171108.belns"
DEFINE NAMESPACE SCOMP          AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/selventa-named-complexes/selventa-named-complexes-20170725.belns"
DEFINE NAMESPACE SFAM           AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/selventa-protein-families/selventa-protein-families-20170725.belns"

# Namespaces defined with regular expressions
# -------------------------------------------
DEFINE NAMESPACE DBSNP          AS PATTERN "rs[0-9]+"
DEFINE NAMESPACE TAXONOMY       AS PATTERN "^\d+$"
DEFINE NAMESPACE UNIPROT        AS PATTERN "^([A-N,R-Z][0-9]([A-Z][A-Z, 0-9][A-Z, 0-9][0-9]){1,2})|([O,P,Q][0-9][A-Z, 0-9][A-Z, 0-9][A-Z, 0-9][0-9])(\.\d+)?$"
DEFINE NAMESPACE PUBCHEM        AS PATTERN "^\d+$"

###############
# Annotations #
###############

# Annotations defined with regular expressions
# --------------------------------------------
DEFINE ANNOTATION Species       AS PATTERN "^\d+$"

# Annotations hosted on https://arty.scai.fraunhofer.de/artifactory/bel/annotation
# --------------------------------------------------------------------------------
DEFINE ANNOTATION Anatomy       AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno"
DEFINE ANNOTATION CellLine      AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-line/cell-line-20170511.belanno"
DEFINE ANNOTATION CellStructure AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-structure/cell-structure-20170511.belanno"
DEFINE ANNOTATION Cell          AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20170511.belanno"
DEFINE ANNOTATION Confidence    AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno"
DEFINE ANNOTATION Disease       AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20170511.belanno"
DEFINE ANNOTATION Gender        AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/gender/gender-1.0.0.belanno"
DEFINE ANNOTATION MeSHAnatomy   AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno"
DEFINE ANNOTATION MeSHDisease   AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20170511.belanno"
DEFINE ANNOTATION Subgraph      AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/neurommsig/neurommsig-1.0.3.belanno"
DEFINE ANNOTATION TextLocation  AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/text-location/text-location-1.0.1.belanno"

##############
# Statements #
##############

SET STATEMENT_GROUP = "Sandra"

# Add statements below this comment

SET Citation = {"PubMed", "Biol Psychiatry. 2001 Feb 1;49(3):200-10", "11230871"}

SET Evidence = "Experimental data suggest that the nAChRs might act as
neuromodulators in communicative processes in the brain
(Kaiser et al 2000; Lindstro¨m 1997; Wonnacott 1997)"
p(FPLX:CHRN) -- a(MESH:"Neurotransmitter Agents")

SET Evidence = "The nAChRs are found to be involved in a complex range of
central nervous system disorders including Alzheimer’s
disease (AD), Parkinson’s disease, schizophrenia,
Tourette’s syndrome, anxiety, depression, and epilepsy
(Newhouse and Kelton 2000; Newhouse et al 1997; Paterson and Nordberg 2000)"
p(FPLX:CHRN) -- path(MESH:"Alzheimer Disease")
p(FPLX:CHRN) -- path(MESH:"Parkinson Disease")
p(FPLX:CHRN) -- path(MESH:Schizophrenia)
p(FPLX:CHRN) -- path(MESH:"Tourette Syndrome")
p(FPLX:CHRN) -- path(MESH:Anxiety)
p(FPLX:CHRN) -- path(MESH:Depression)
p(FPLX:CHRN) -- path(MESH:Epilepsy)

SET Evidence = "Interestingly enough, a
considerable body of evidence exists to suggest that the
nAChRs are involved in cognitive and memory functions
(Levin 2000; Newhouse and Kelton 2000; Newhouse et al
1997; Sahakian and Coull 1994)"
p(FPLX:CHRN) -- bp(GO:cognition)
p(FPLX:CHRN) -- bp(GO:memory)

SET Evidence = "All three ligands appeared to bind to a common
high-affinity binding site, which most likely represents
binding to the nAChR alpha4 subunits"
#ligands: [3H]nicotine, [3H]epibatidine and [3H]cytisine
complex(a(CHEBI:nicotine),p(HGNC:CHRNA4))
complex(a(CHEBI:epibatidine),p(HGNC:CHRNA4))
complex(a(CHEBI:cytisine),p(HGNC:CHRNA4))

SET Evidence = "A significantly greater binding for [3H]nicotine and [3H]epibatidine than for
[3H]cytisine is observed in areas of the primary motor
cortex, layer 111b of the occipital cortex, and layer V of
the superior temporal sulcus, most likely representing binding of an additional nAChR site"
SET MeSHAnatomy = {"Motor Cortex","Occipital Lobe","Temporal Lobe"}
complex(a(CHEBI:nicotine),p(FPLX:CHRN))
complex(a(CHEBI:epibatidine),p(FPLX:CHRN))
complex(a(CHEBI:cytisine),p(FPLX:CHRN))
UNSET MeSHAnatomy

SET Evidence = "High levels of [3H]nicotine binding have been observed in layers 1 and
V1 of the primary cortex, deeper layer V of the primary
cortex, layer 111 of the superior temporal sulcus, and layer
V1 of the parietal cortex. This suggests the presence of an
additional third nAChR site in the human cortex (Sihver et al 1998b) that may be the alpha7 nAChR subtype"
SET MeSHAnatomy = {"Motor Cortex","Temporal Lobe","Parietal Lobe"}
complex(a(CHEBI:nicotine),p(HGNC:CHRNA7))
UNSET MeSHAnatomy

SET Evidence = "A significant decrease in [3H]epibatidine binding has been observed with aging
in the human cortical brain regions and cerebellum (Marutle et al 1998)"
SET MeSHAnatomy = {"Cerebellum","Cerebral Cortex"}
bp(GO:aging) negativeCorrelation complex(a(CHEBI:epibatidine),p(FPLX:CHRN))
UNSET MeSHAnatomy

SET Evidence = "The levels of alpha4 and alpha7 nAChR mRNA
showed a decrease with aging, whereas the levels of alpha3
mRNA were unchanged in the elderly brain relative to the
fetal brain (Hellstro¨m-Lindahl et al 1998)"
SET MeSHAnatomy = "Brain"
bp(GO:aging) causesNoChange r(HGNC:CHRNA3)
bp(GO:aging) negativeCorrelation a(HBP:"alpha-4-containing nAChR")
bp(GO:aging) negativeCorrelation a(HBP:"alpha-7-containing nAChR")
UNSET MeSHAnatomy

SET MeSHDisease = "Alzheimer Disease"
SET MeSHAnatomy = "Cerebral Cortex"

SET Evidence = "A consistent, significant loss of nAChRs has been observed
in cortical autopsy brain tissue from AD patients
relative to age-matched healthy subjects (Nordberg and Winblad 1986)"
path(MESH:"Alzheimer Disease") negativeCorrelation p(FPLX:CHRN)

SET Evidence = "The cortical nAChR deficits significantly correlate with cognitive impairment
in AD patients (Nordberg, in press; Nordberg et al 1995, 1997)"
p(FPLX:CHRN) negativeCorrelation path(MESH:"Cognitive Dysfunction")

SET Evidence = "When the laminar binding distribution of [3H]nicotine,
[3H]epibatidine, and [3H]cytisine was measured in AD
cortical autopsy tissue, marked reductions were observed
relative to control brains (Sihver et al 1999c) (Figure 1)"
path(MESH:"Alzheimer Disease") negativeCorrelation p(HGNC:CHRNA3)
p(HGNC:CHRNA4) -| complex(a(CHEBI:cytisine),p(FPLX:CHRN))

UNSET MeSHDisease

SET Evidence = "In addition, a marked reduction in the laminar distribution of
[3H]epibatidine binding was observed in control cortical tissue with aging (Figure 1)"
bp(GO:aging) negativeCorrelation complex(a(CHEBI:epibatidine),p(FPLX:CHRN))

UNSET MeSHAnatomy

SET Evidence = "beta-Amyloid (Abeta) is also an important factor, which may
initiate and promote AD (Selkoe 1999)"
a(CHEBI:"amyloid-beta") -> path(MESH:"Alzheimer Disease")

SET Evidence = "This mutation at codon
670/671 on the APP gene on chromosome 21 was discovered
in a Swedish family, and the mutation is unique in the
sense that it is the only AD mutation that has been shown
to alter the APP metabolism, resulting in an overexpression
of the amyloid leading to plaque formation (Mullan et al 1992)"
p(HGNC:APP,var("p.Lys670Asn"),var("p.Met671Leu")) -- act(p(HGNC:APP))
p(HGNC:APP,var("p.Lys670Asn"),var("p.Met671Leu")) -> path(MESH:"Plaque, Amyloid")

SET Evidence = "Significant reductions in the number of nAChRs
were measured in cortical regions of Swedish APP 670/
671 mutation (273% to 287%) (Marutle et al 1999)"
SET MeSHAnatomy = "Cerebral Cortex"
p(HGNC:APP,var("p.Lys670Asn"),var("p.Met671Leu")) negativeCorrelation p(FPLX:CHRN)
UNSET MeSHAnatomy

SET Evidence = "A decrease in the protein levels of the alpha3 and alpha4
nAChR subunits was recently measured in the temporal
cortex and of the alpha3, alpha4, and alpha7 nAChR subtypes in the
hippocampi of AD brains relative to age-matched control subjects (Guan et al 2000b)"
SET MeSHAnatomy = "Temporal Lobe"
path(MESH:"Alzheimer Disease") negativeCorrelation p(HGNC:CHRNA3)
path(MESH:"Alzheimer Disease") negativeCorrelation p(HGNC:CHRNA4)
SET MeSHAnatomy = "Hippocampus"
path(MESH:"Alzheimer Disease") negativeCorrelation p(HGNC:CHRNA3)
path(MESH:"Alzheimer Disease") negativeCorrelation p(HGNC:CHRNA4)
path(MESH:"Alzheimer Disease") negativeCorrelation p(HGNC:CHRNA7)
UNSET MeSHAnatomy

SET Evidence = "A decrease in protein levels of
the alpha4 nAChR but not of the alpha3 and alpha7 nAChRs was
reported by Martin-Ruiz et al (1999)"
path(MESH:"Alzheimer Disease") negativeCorrelation a(HBP:"alpha-4-containing nAChR")

SET Evidence = "Lee et al (2000) recently also reported a significant decrease in the
alpha7 nAChR protein level of the AD hippocampus"
SET MeSHAnatomy = "Hippocampus"
path(MESH:"Alzheimer Disease") negativeCorrelation a(HBP:"alpha-7-containing nAChR")
UNSET MeSHAnatomy

SET Evidence = "Interestingly, a reduction in the protein level of alpha7 has also
been measured in the frontal cortex of patients with
schizophrenia (Guan et al 1999), whereas no decrease was
measured in the alpha4 nAChR protein level (Guan et al 1999)"
SET MeSHAnatomy = "Frontal Lobe"
path(MESH:Schizophrenia) negativeCorrelation a(HBP:"alpha-7-containing nAChR")
path(MESH:Schizophrenia) causesNoChange a(HBP:"alpha-4-containing nAChR")
UNSET MeSHAnatomy

SET Evidence = "Examination of the regional expression of mRNA of the
nAChR alpha4 and alpha3 subunits has shown no difference in
autopsy AD brain tissue in any region analyzed (Hellstro
¨m-Lindahl et al 1999; Terzano et al 1998), whereas the
level of the alpha7 mRNA was significantly higher in the
hippocampus (Hellstro¨m-Lindahl et al 1999)"
SET MeSHAnatomy = "Hippocampus"
path(MESH:"Alzheimer Disease") positiveCorrelation r(HGNC:CHRNA7)
path(MESH:"Alzheimer Disease") causesNoChange r(HGNC:CHRNA3)
path(MESH:"Alzheimer Disease") causesNoChange r(HGNC:CHRNA4)
UNSET MeSHAnatomy

SET Evidence = "Possible factors such as amyloid peptide accumulation,
hyperphosphorylation of tau protein, oxidative stress, and
modification of cell membrane during the development of
AD may be related to decreased protein levels of nAChRs
(Farooqui et al 1995; Smith et al 1996)"
a(MESH:"Amyloid beta-Peptides") negativeCorrelation p(FPLX:CHRN)
p(HGNC:MAPT,pmod(HBP:hyperphosphorylation)) negativeCorrelation p(FPLX:CHRN)
bp(GO:"response to oxidative stress") negativeCorrelation p(FPLX:CHRN)

SET Evidence = "Interestingly enough, lipid peroxidation has been shown to decrease the
number of nAChRs in PC12 cells (Guan et al 2000a)"
bp(MESH:"Lipid Peroxidation") -| p(FPLX:CHRN)

SET MeSHAnatomy = "Cerebral Cortex"

SET Evidence = "Positron emission tomography
studies have revealed a reduced cortical acetylcholinesteserase
activity in AD patients (Iyo et al 1997; Kuhl et al 1999)"
path(MESH:"Alzheimer Disease") -| act(p(HGNC:ACHE))

SET Evidence = "A progressive loss of cortical acetylcholinesterase
activity has been observed in AD patients with
cognitive decline (Shinotoh et al 2000)"
path(MESH:"Alzheimer Disease") negativeCorrelation act(p(HGNC:ACHE))
path(MESH:"Alzheimer Disease") negativeCorrelation bp(GO:cognition)

UNSET MeSHAnatomy

SET Evidence = "The presynaptic vesicular acetylcholine transporter vesamicol ([123I]iodobenzovesamicol)
has been used in vivo as a marker of presynaptic cholinergic activity in single photon emission
computed tomography (SPECT) studies (Kuhl et al 1996)"
a(PUBCHEM:5662) -- bp(GO:"synaptic transmission, cholinergic")

SET Evidence = "The loss in cortical acetylcholinesterase activity was less pronounced
in mildly demented AD patients relative to autopsy material and did not strictly correlate with cerebral
glucose metabolism impairment (Kuhl et al 1999)"
path(MESH:"Alzheimer Disease") -| act(p(HGNC:ACHE))

SET Evidence = "Selective cortical deficits
in [11C]nicotine binding are often observed by PET early
in the course of the AD disease (Figure 3A)"
#binding to CHRN
path(MESH:"Alzheimer Disease") -| complex(a(CHEBI:nicotine),p(FPLX:CHRN))

SET Evidence = "A significant correlation can be observed between cognitive function
and nicotinic receptor binding (k2*) (Figure 3A)"
complex(a(CHEBI:nicotine),p(FPLX:CHRN)) -- bp(GO:cognition)

SET Evidence = "A ligand with a selectivity for the alpha4beta2 nAChRs
would be particularly preferable because the alpha4beta2 has
been recognized as the predominant subtype that is deficient
in AD (for a review, see Sihver et al 2000)"
path(MESH:"Alzheimer Disease") -| a(HBP:"alpha-4 beta-2 nAChR")

SET Evidence = "Cholinergic therapy is based on the assumption
that low levels of acetylcholine are responsible for the
cognitive decline associated with AD"
SET MeSHDisease = "Alzheimer Disease"
a(CHEBI:acetylcholine) negativeCorrelation bp(GO:cognition)
UNSET MeSHDisease

SET Evidence = "It is likely that the
therapeutic benefit of cholinesterase inhibitors occurs at
least in part through activation of the nAChRs, by the
direct action of increased levels and/or through a direct
activation of the allosteric site on the nAChR (Maelicke et al 1995, 2000)"
# cholinesterase inhibitors: tacrine,donepezil,rivastigmine,galanthamine
a(CHEBI:tacrine) -> act(p(HGNC:ACHE))
a(CHEBI:donepezil) -> act(p(HGNC:ACHE))
a(CHEBI:rivastigmine) -> act(p(HGNC:ACHE))
a(CHEBI:galanthamine) -> act(p(HGNC:ACHE))

SET Evidence = "In addition, PET studies also have revealed an improvement
in nAChRs in AD patients during long-term treatment
with cholinesterase inhibitors such as tacrine and NXX-
066 (Nordberg 2000; Nordberg et al 1992, 1998)"
# NXX-066: quilostigmine
SET MeSHDisease = "Alzheimer Disease"
a(CHEBI:tacrine) -> p(FPLX:CHRN)
a(PUBCHEM:132228) -> p(FPLX:CHRN)
UNSET MeSHDisease

SET Evidence = "Since an
enhanced activity of acetylcholinesterase has been measured
in cerebrospinal fluid following long-term treatment
with tacrine (Nordberg et al 1999), possibly as a result of
an increased acetylcholinesterase gene expression, it might
be an advantage to use drugs interacting with nAChRs"
SET MeSHAnatomy = "Cerebrospinal Fluid"
a(CHEBI:tacrine) -> act(p(HGNC:ACHE))
UNSET MeSHAnatomy

SET MeSHDisease = "Alzheimer Disease"

SET Evidence = "Nerve growth factor intraventricularly administered to AD
patients for 3 months resulted in an increased [11C]nicotine
binding (Eriksdotter-Jo¨nhagen et al 1998), whereas
treatment with the 5-HT3 blocker ondansetron showed a
decreased number of cortical nAChRs (Nordberg et al 1997)"
a(MESH:"Nerve Growth Factor") -> complex(a(CHEBI:nicotine),p(FPLX:CHRN))
SET MeSHAnatomy = "Cerebral Cortex"
a(CHEBI:Ondansetron) -| p(FPLX:CHRN)
UNSET MeSHAnatomy

SET Evidence = "The potential therapeutic benefit of nAChR stimulation
in AD is based upon the fact that nicotine improves
memory in animals, healthy subjects, and AD patients
(Levin 2000; Newhouse and Kelton 2000; Newhouse et al
1997; Rusted and Warburton 1992)"
a(CHEBI:nicotine) -> bp(GO:memory)

UNSET MeSHDisease

SET Evidence = "Activation of the nAChR modulates the release of several neurotransmitters
(Kaiser et al 2000; Wonnacott 1997) that mediate important
physiologic mechanisms including cognitive functions"
act(p(FPLX:CHRN)) reg tloc(a(CHEBI:neurotransmitter),fromLoc(GO:intracellular),toLoc(GO:"extracellular region"))
a(CHEBI:neurotransmitter) -- bp(GO:cognition)

SET MeSHDisease = "Alzheimer Disease"

SET Evidence = "Administration of the nicotinic antagonist
mecamylamine to elderly subjects and AD patients has
produced cognitive impairment (Newhouse and Kelton
2000)"
a(CHEBI:Mecamylamine) -| bp(GO:cognition)

SET Evidence = "Acute administration of nicotine to AD patients has
resulted in a measurable short-term improvement in learning,
memory, and attentional performance (Jones et al
1992)"
a(CHEBI:nicotine) -> bp(GO:memory)
a(CHEBI:nicotine) -> bp(GO:learning)
a(CHEBI:nicotine) -> path(MESH:Attention)

SET Evidence = "Recently, the nicotinic agonist ABT-
418 improved verbal learning and memory on a selective
reminding task in AD patients (Potter et al 1999)"
a(PUBCHEM:119380) -> path(MESH:"Verbal Learning")
a(PUBCHEM:119380) -> bp(GO:memory)

SET Evidence = "Estrogen, which in epidemiologic studies has
been shown to reduce the risk of AD (Henderson 1997),
has in experimental studies in PC 12 cells shown neuroprotective
effects against Abeta toxicity that are at least
partly mediated by the alpha7 subtype nAChR (Svensson and Nordberg 1998)"
a(CHEBI:estrogen) -| path(MESH:"Alzheimer Disease")
a(CHEBI:estrogen) -| act(a(CHEBI:"amyloid-beta"))
a(HBP:"alpha-7-containing nAChR") reg act(a(CHEBI:"amyloid-beta"))

UNSET MeSHDisease


##########################################################


UNSET STATEMENT_GROUP
